Investing
Cathie Wood's ARK Invest Sells Over 350,000 Shares of Takeda Pharma
Published:
Last Updated:
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 350,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Wednesday, as the share price of this fund traded relatively flat in the day’s session. Its share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 366,228 shares of Takeda. At Wednesday’s closing price, this would have valued this sale at roughly $6.2 million. This is only a small fraction of the total holdings. This fund is up 84% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | TCSLI | TCS GROUP HOLDING PLC | 35,354 |
| ARKG | NVS | NOVARTIS AG | 128,903 |
| ARKG | PSTI | PLURISTEM THERAPEUTICS INC | 1,357 |
| ARKG | SRPT | SAREPTA THERAPEUTICS INC | 22,178 |
| ARKG | TAK | TAKEDA PHARMACEUTICAL CO LTD | 366,228 |
| ARKQ | GLEO | GALILEO ACQUISITION CORP | 325,800 |
| ARKQ | NVDA | NVIDIA CORP | 4,050 |
| ARKQ | RAVN | RAVEN INDUSTRIES INC | 12,814 |
| ARKQ | TCEHY | TENCENT HOLDINGS LTD | 36,315 |
| ARKW | TCEHY | TENCENT HOLDINGS LTD | 46,793 |
| ARKW | PSTG | PURE STORAGE INC | 187,131 |
| ARKW | NET | CLOUDFLARE INC | 69,294 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
